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Outsourcing of drug discovery processes offers a vast opportunity to scientists to develop and
commercialize new and innovative methods and technologies as well as other discoveries that
could be of use to pharmaceutical industry. Specifically, this is of special value for investiga-
tions that are either too complex or too infrequent to be performed in-house and can be carried
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INTRODUCTION
In the last few decades, R&D costs have skyrocketed
and it is becoming increasingly harder to put a new drug
on the market (Figure 1).1 The reasons for this are nu-
merous. Regulatory requirements are more rigorous, ask-
ing for more detailed non-clinical and clinical data be-
fore approving a new drug. Product and production quality
is more demanding. Genomics and proteomics together
with new technology platforms have increased the cost
of the early discovery phase. All of this has raised the
cost of drug development by about 250 % in the last ten
years.2
On the other hand, many best-selling drugs that are
the main source of R&D expenditure will be losing their
patent protection within the next few years. In this envi-
ronment, pharmaceutical companies are trying to cut
costs and speed up the drug discovery process either by
acquiring other companies and thus overcoming the lack
of expertise and knowledge and/or by outsourcing part
of their activities. At the same time, Contract Research
Organizations (CRO) have emerged that offer activities
within the drug discovery process with great expertise
and specialized knowledge in specific areas at a compet-
itive price. The CRO industry is growing rapidly and
this is expected to continue in the years to come.3
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Figure 1. Growth in R&D expenditures is not followed by the num-
ber of new chemical entities on the market.
What Activities Are Outsourced, When and Why?
First of all, a strategic decision has to be taken as to
what will be outsourced and what will remain in-house.
Scientific methods and technologies are developing and
improving every day; they are expensive, sometimes com-
plicated and it is impossible to implement all of them in-
house, hence CROs represent a perfect solution to over-
come this gap. Skills or activities that are needed rarely
or for a short period of time are better outsourced than
developed in-house, thereby lowering the cost. When
there is internal lack of knowledge, time, people or equip-
ment, outsourcing is also the best option. CROs are usually
highly qualified and experienced in their field since they
have a team of people working within a narrow range of
activities, which make them sometimes unbeatable com-
petitors.4
Many pharmaceutical companies have established
whole departments that organize and deal with contract
research as part of their outsourcing. The main reason
for this is to sort out and control an increasing number of
contracts and to lower the costs by finding the best part-
ner companies for their needs. The task of the outsourc-
ing specialist is to support the goals of programs and
projects by facilitating collaboration with outsourcing
providers. Searching and selecting the CROs, negotiat-
ing the prices and other contract provisions, such as lia-
bility, intellectual property rights, confidentiality issues,
etc., and establishing and maintaining good relationships
with CROs through meetings and other means of com-
munication are some of the tasks that outsourcing spe-
cialists perform.5
Relationships between »sponsors« and »vendors«
are changing all the time. The first generation of collabo-
rations was a classical »sponsor/vendor« relationship,
but nowadays this is becoming more and more a partner-
ship, which assumes a joint spirit and risk-taking that
brings more value to both parties.
What Do Contract Research Organizations Do,
Who Are They?
There are a number of small to large CRO companies,
from one-activity laboratories in some specific fields to
the global multiple activity companies able to cover a
large part of the drug development process. Classical
CROs that perform clinical trials get the most money
from the pharmaceutical industry since clinical trials are
large and complex studies involving enormous numbers
of patients and data. These CROs (also called »Clinical
Research Organizations«) select and coordinate investi-
gation sites and physicians involved in the studies, col-
lect and manage the data and together with the sponsor
generate a study report. Other CROs perform non-clini-
cal studies consisting of safety/toxicology testing; phar-
macology (pharmacokinetics, pharmacodynamics) and
other in vitro and in vivo tests required by regulatory ag-
encies and satisfying all of their quality requirements. In
addition, there are companies that up-scale the laboratory
synthesis of compounds that need to be tested in clinical
trials and produce the required quantities of the active
compound; analytical labs, which are able to perform
analyses in accordance with strict regulatory and quality
requirements (GLP – »good laboratory practice«); com-
panies that package and prepare clinical trial material
(new compound, reference compound and placebo), etc.6
Among CROs, there are also a large number of new
innovative and science-based companies, founded by one
or a few scientists that have made their own or have ap-
plied somebody else’s discovery, developed it into prac-
tical technology and finally established an innovative
company – a combination between knowledge and ap-
plication. There are many examples of such innovative
companies that usually start as »spin-offs« from the uni-
versities or big pharmaceutical companies. One such uni-
versity spin-off is »Dual Systems« in Switzerland, whose
co-founder is the Croatian molecular biologist Igor
Stagljar. The company uses a yeast two-hybrid system to
study the influence of a drug on the interaction between
two proteins. Another such company is »CXR biosci-
ences« in the UK that developed a transgenic mouse
model, based on inactivated hepatic P-450 enzymes which
are involved in the metabolism of many drugs. By test-
ing drug candidates in their proprietary model, it is pos-
sible to check toxicity and bioavailability of the intact
compound and distinguish it from the effect of its me-
tabolites. »Ifcos«, a Canadian/German company is try-
ing to develop »in silico« models for simulation of intra-
cellular interactions and pathways that would enable cli-
ents to check the influence of up- or down-regulation of
any gene within the cell on its interaction with upstream
or downstream proteins. Big pharmaceutical companies’
spin-off examples are »Rosseta Inpharmatics«, a wholly
owned subsidiary of Merck that develops and imple-
ments technologies for improvement of drug discovery
and Pharmacia’s »Biovitrum«, a biotech company that
combines the experience of a big pharmaceutical com-
pany with the flexibility of modern biotechs. RNAi (small
RNA interference) is becoming a hot topic not only for
target determination and validation, but efforts are being
made to develop it as a therapy, especially for »undrug-
gable« targets. New companies have appeared based on
this new discovery as producers of kits for using the
technology in research or for the development of an RNAi
as a therapeutic. There are a number of other examples
of the transfer of a scientist’s discoveries and knowledge
to successful companies; a pool of companies in Cam-
bridge Science Park, UK, is an excellent representative
of this approach. Many of these companies were estab-
lished as a consequence of discoveries closely related to
the needs of the pharmaceutical industry.
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What Determines the Selection of a Particular CRO?
Selection of a CRO is the most challenging task in the
outsourcing process. There are many parameters specific
to each study that have to be taken into account.
The CRO should work in compliance with the quality
standards required by regulatory agencies (GLP, GMP,
etc.) and demonstrate ability and willingness to perform
the requested activity. Their experience is often a good
reference. A further criterion is cost-effectiveness (com-
parison between quality and price). For some studies the
price is crucial and for the others quality or timing is
more important.
If the CRO offers completely new and unique ideas
and the expected outcome of a study can bring added va-
lue to the project, this may be a unique decision-making
criterion.
Finally, it is very important to establish a friendly
and »easy-going« relationship between the partners and
definitely the best reference for the CRO is its own ex-
perience and track record. Performance metrics intro-
duced by relevant experts in the field have shown that
strong working relationships bring about 25 % higher
value than poor relationships between partners.7
PLIVA and Outsourcing
PLIVA, as a global company, has developed a wide net-
work of outsourcing partners. In terms of R&D, the out-
sourcing money is spent predominantly on clinical trials
and non-clinical testing of drug candidates that, due to
regulatory requirements, cannot be performed »in-house«.
PLIVA has always, since its very beginnings, had
good collaboration with its surrounding scientific com-
munity. This policy has not changed during the, some-
times turbulent, recent past for industry and science in
Croatia. Nevertheless, the development and strengthen-
ing of PLIVA’s R&D and the increasing use of outsourc-
ing that has followed global trends, has not been matched
sufficiently by the development of Croatian science to-
wards innovation and applicability. There are a number
of reasons for this. Our scientists were educated in an
environment that did not pay enough attention to protec-
tion of intellectual property rights or the possibilities of
commercializing their discoveries. There is no doubt that
fundamental research is very important to all aspects of
life, but there should be a balance between basic and ap-
plied research. The Croatian Ministry of Science started
a few years ago with »RAZUM«, programs that encour-
age the establishment of small businesses based on know-
ledge, innovation and new technologies; but in natural
sciences, biotechnology and non-clinical discovery phase
there is a lot of space for the formation of small biotech
companies which would provide services to the pharma-
ceutical industry within Croatia, and also to the industry
in neighboring countries, as exemplified by develop-
ments in Hungary, Slovenia and the Czech Republic. If
this were the case, PLIVA would be able to improve the
ratio between its spending on outsourcing in Croatia and
in other countries that now amounts to only about 3–4 %
(Figure 2).
PLIVA will continue its fruitful and good collabora-
tion with its scientific surroundings, in particular with
the Rudjer Bo{kovi} Institute, Medical Schools of Zag-
reb and Rijeka, Faculty of Pharmacy and Biochemistry,
Zagreb, Faculty of Science, Zagreb, and is willing to ex-
tend that collaboration considerably if the services offer-
ed are competitive with those found in other countries.
CONCLUSION
Outsourcing, collaboration and partnership are relatively
new, but overwhelmingly accepted approaches in all mo-
dern industries and as a part of the globalization process,
represent a cost-effective opportunity for developing co-
untries to participate and become competitive. Outsourcing
of the drug discovery process is a challenge to scientists
to develop and commercialize their new and innovative
methods and technologies along with other discoveries
that could be used by the pharmaceutical industry.
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Uporaba vanjskih usluga u istra`ivanju i razvoju u farmaceutskoj industriji.
Mogu}nosti i izazovi
Smiljka Viki}-Topi}
Uporaba vanjskih usluga u procesu razvoja novih lijekova pru`a brojne prilike znanstvenicima za razvijanje i
komercijalizaciju inovativnih metoda i tehnologija te otvara put k novim otkri}ima, koja se mogu upotrijebiti u
farmaceutskoj industriji. To je osobito dragocjeno u istra`ivanjima koja se u farmaceutskoj industriji rijetko
provode ili su preslo`ena da bi se isplatilo njihovo uvo|enje u vlastitome laboratoriju. Uporabom vanjskih us-
luga znanstvenika mnoga se farmaceutska istra`ivanja mogu provesti br`e i djelotvornije.
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